Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial - Report - MDSpire

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

  • By

  • Oded Icht

  • Alexander Sun

  • Philip Wong

  • Andrew McPartlin

  • Thiago Pimentel Muniz

  • Anna Spreafico

  • Samuel D. Saibil

  • J. Nicholas Lukens

  • Sana D Karam

  • John De Almeida

  • Marcus O. Butler

  • C. Jillian Tsai

  • July 6, 2026

  • 0 min

Share

Clinical Report: Evaluating Radiotherapy for Oligoprogression in Melanoma

Overview

This phase 2 trial investigates the efficacy of stereotactic body radiation therapy (SBRT) in improving progression-free survival (PFS) for metastatic melanoma patients experiencing oligoprogression while on systemic therapy. The study aims to enroll 52 patients and assess clinical outcomes including overall survival, treatment tolerance, and quality of life over a follow-up period of 24 months.

Background

Oligoprogression occurs when cancer progresses at a limited number of sites while the majority remains stable under systemic therapy.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • The trial is designed to evaluate the impact of SBRT on PFS in metastatic melanoma patients with oligoprogression.
  • Eligible patients have ≤10 extracranial oligoprogressive sites and are on first-line systemic therapy.
  • The primary endpoint is PFS, defined as the time from enrollment to further disease progression.
  • Secondary endpoints include overall survival, treatment tolerance, and quality of life.
  • Serial blood samples will be collected for exploratory analyses of circulating tumor DNA and immune profiling.

Clinical Implications

Understanding the effects on PFS and other clinical outcomes will be important for future management strategies.

Conclusion

The CURB-Melanoma trial aims to clarify the role of SBRT in extending PFS for patients with oligoprogressive metastatic melanoma.

Related Resources & Content

  1. ClinicalTrials.gov, 2023 -- Evaluating Radiotherapy as a Consolidative Approach to Manage Oligoprogression in Metastatic Melanoma Patients
  2. The ASCO Post — Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer
  3. The ASCO Post — Local Radiotherapy May Help Control Oligometastatic Breast Cancer
  4. the asco post — Metastasis-Directed Radiotherapy for Oligometastatic Clear Cell Renal Cell Carcinoma
  5. The Role of Radiotherapy in Advanced Bladder Cancer with Metastasis
  6. Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer
  7. Local Radiotherapy May Help Control Oligometastatic Breast Cancer
  8. Metastasis-Directed Radiotherapy for Oligometastatic Clear Cell Renal Cell Carcinoma
  9. The Role of Radiotherapy in Advanced Bladder Cancer with Metastasis
  10. 2025 EADO Guidelines for Melanoma Treatment
  11. Randomized Study of Stereotactic Body Radiation Therapy in Patients With Oligoprogressive Metastatic Cancers
  12. Stereotactic body radiation therapy for oligometastatic melanoma: a real-world study

Original Source(s)

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

  • by Oded Icht, Alexander Sun, Philip Wong, Andrew McPartlin, Thiago Pimentel Muniz, Anna Spreafico, Samuel D. Saibil, J. Nicholas Lukens, Sana D Karam, John De Almeida, Marcus O. Butler, C. Jillian Tsai

  • July 6, 2026

Related Content

Imaging-mediated genetic effects link brain microstructure, metabolic profiles, and regional transcription to glioma susceptibility

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans

Prostate Cancer Screening—Where We’ve Been, Where We Are, and What Comes Next